FDA Approves Gilead's Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen; Also Approved by European Comission
December 13, 2013 at 16:32 PM EST
Gilead Sciences (Nasdaq: GILD ) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera^® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA
